Cite
MLA Citation
Christoph Röllig et al.. “Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.” Lancet oncology, vol. 16, no. 16, 2015, pp. 1691–1699. http://access.bl.uk/ark:/81055/vdc_100029474807.0x000038